8-K: Sight Sciences Extends Interest-Only Loan Period

Sight Sciences, Inc. secured a six-month extension of its interest-only loan period with Hercules Capital, Inc. and reallocated an undrawn $10 million tranche, maintaining a $65 million credit facility.

Summary

• Entered into a third amendment to the Loan and Security Agreement with Hercules Capital, Inc. and its affiliates on September 30, 2025.
• Extended the interest-only period by an additional six months, now until February 1, 2027.
• Reallocated an undrawn and previously unavailable $10.0 million tranche.
• Increased the amount available to draw through the interest-only period for Tranche 3 from $15.0 million to $25.0 million.
• Tranche 3 advances are available in minimum increments of $5.0 million, subject to the sole approval of Hercules' investment committee.
• The maximum aggregate principal amount of the senior secured term loan facility remains at $65.0 million.
• Paid Hercules Capital, Inc. a fee of $50,000 for the benefit of the lenders, plus certain costs and expenses, as consideration for the amendments.
• Deleted references to 'Interest Only Extension Conditions', 'Performance Milestone II', 'Tranche 2 Availability Period', and 'Tranche 2 Commitment' from the Loan Agreement.
• Amended the 'Board Approved Forecast' definition to include revenue projections corresponding to covenant levels at least [redacted]% higher than prior year's covenant levels for each calendar month ending during 2026.

Sentiment

Score: 7

Explanation: The extension of the interest-only period and increased flexibility for additional draws provide a positive boost to the company's liquidity and financial runway, despite the associated fee and reliance on lender approval for future draws.

Positives

• Extended the interest-only period by six months, providing additional liquidity runway and financial flexibility until February 1, 2027.
• Increased the flexibility to draw additional funds under Tranche 3 by $10.0 million, raising the total available for Tranche 3 to $25.0 million, which could support future operations or growth initiatives.
• Maintained the overall $65.0 million credit facility, indicating continued lender support.

Negatives

• Incurred a $50,000 amendment fee and other associated costs and expenses.
• Additional draws under Tranche 3 are subject to the sole and unfettered discretion of Hercules' investment committee, introducing uncertainty regarding future funding access.
• The deletion of 'Performance Milestone II' and 'Tranche 2 Commitment' suggests that certain prior performance targets were not met or are no longer relevant, potentially indicating past operational challenges.

Risks

• Forward-looking statements are subject to considerable risks and uncertainties, which could cause actual results to differ materially.
• The availability of additional Tranche 3 draws is contingent on the sole approval of Hercules' investment committee, which is not guaranteed.
• The company's actual results, performance, or achievements may be materially different from any future results, performance, or achievements predicted, assumed, or implied by forward-looking statements.
• Important factors discussed under 'Risk Factors' in the company's SEC filings may impact future performance.

Future Outlook

The company anticipates the extension of the interest-only period under the Hercules Loan Agreement to February 1, 2027, and the availability of additional draws under the Hercules Loan Agreement during this period.

Management Comments

• Management believes these forward-looking statements are based upon reasonable assumptions at the time they are made, but cannot guarantee their accuracy or completeness.

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential positive impact due to extended liquidity runway and reduced near-term cash outflow for principal payments, but also potential dilution if warrants are issued with Tranche 3 advances (as referenced in Addendum 1, Section 11).
• Creditors (Hercules Capital, Inc.): Received an amendment fee and maintained their secured position, with continued discretion over future Tranche 3 draws.
• Operations: Extended financial flexibility could support ongoing operations and strategic initiatives by deferring principal repayments.

Next Steps

• Continue to operate under the amended Loan and Security Agreement.
• Potentially request Tranche 3 advances, subject to Hercules' investment committee approval.
• Begin making principal payments on the loan starting February 1, 2027.

Key Dates

Recommendation

The extension of the interest-only period provides Sight Sciences with additional financial flexibility and runway, which is a positive for near-term liquidity management. However, the need for such an amendment, the associated fee, and the reliance on lender discretion for future draws suggest ongoing financial management challenges. Without further details on operational performance or a clear path to profitability, a 'hold' recommendation is prudent, allowing investors to monitor how the company utilizes this extended period.

Keywords

Sight Sciences, Hercules Capital, Loan Agreement, Debt Financing, Credit Facility, Interest-Only Extension, Tranche 3, SEC Filing, 8-K, Biotech, Medical Devices